Strategic Growth GT Medical Technologies is expanding rapidly with a recent $100 million Series E funding round led by Viking Global Investors, signaling increasing capacity for market expansion, clinical adoption, and potential new product lines or geographies that sales teams can target.

Clinical Evidence The company presents data from the ROADS trial at ASCO26, highlighting robust clinical validation for GammaTile. This provides a strong consultative basis to engage hospitals and cancer centers on cost-benefit and patient outcomes.

Market Penetration GammaTile has achieved adoption at over 100 leading centers since US launch in 2020, indicating a成熟 market footprint and potential upsell opportunities with existing customers and expansion into additional academic and community centers.

Center of Excellence The GammaTile Center of Excellence Program launched in 2025 creates a ready-made partner ecosystem for training, case referrals, and co-marketing, offering structured sales motions and joint demand-generation campaigns.

Financial Momentum With reported revenue in the tens of millions and ongoing Series D proceeds, GT Medical demonstrates financial health and investment capacity to fund direct sales, clinical liaison roles, and expanded customer success resources.